Newsfeeds - Spark Newswire

1 minute read

This Foreboding Sign Looms Over Repligen’s Chart

Today, 11:01 AM

If history is any guide, there may be trouble ahead for shares of Repligen (NASDAQ:RGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

RGEN

1 minute read

SVB Leerink Maintains Outperform on Repligen, Raises Price Target to $325

By Benzinga Newsdesk

Today, 11:01 AM

SVB Leerink analyst Puneet Souda maintains Repligen (NASDAQ:RGEN) with a Outperform and raises the price target from $260 to $325.

RGEN

4 minute read

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug

By Shanthi Rexaline

Today, 11:01 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ALDX

1 minute read

Repligen Q3 Adj. EPS $0.78 Beats $0.64 Estimate, Sales $178.20M Beat $163.97M Estimate

By Bill Haddad

Today, 11:01 AM

Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.64 by 21.88 percent. This is a 95 percent increase over earnings of $0.40 per share from the same

RGEN

19 minute read

Earnings Scheduled For October 28, 2021

By Benzinga Insights

Today, 11:01 AM

Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.

AAPL

4 minute read

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More

By Shanthi Rexaline

Today, 11:01 AM

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.

ABBV